Research progress on classical traditional chinese medicine formula xiaoyaosan in the treatment of depression

Depression is an emotional disorder that is problematic in psychiatry owing to its unclear etiology and unknown pathogenesis. Traditional Chinese medicine formulations such as Xiaoyaosan have been widely used throughout history to treat depression. In this review, we have focused on recent evidences...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 13; p. 925514
Main Authors Chen, Jianbei, Lei, Chaofang, Li, Xiaojuan, Wu, Qian, Liu, Chenyue, Ma, Qingyu, Chen, Jiaxu
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 04.08.2022
Subjects
clinical application
depression
pharmacological mechanism
Pharmacology
research progress
TCM
xiaoyaosan
Online AccessGet full text

Cover

More Information
Summary:Depression is an emotional disorder that is problematic in psychiatry owing to its unclear etiology and unknown pathogenesis. Traditional Chinese medicine formulations such as Xiaoyaosan have been widely used throughout history to treat depression. In this review, we have focused on recent evidences elucidating the links between Xiaoyaosan and the treatment of depression. Data from animal and clinical studies, focusing on the pharmacological mechanisms, clinical applications, and effective materials that form the basis for the treatment of depression are presented and discussed. We found that the antidepressant effects of Xiaoyaosan are related to the effects of monoamine neurotransmitters, regulation of the hypothalamic-pituitary-adrenal axis, neuroplasticity, synaptic plasticity, inflammatory response, neuroprotection, brain-gut axis, regulation of intestinal microbiota, oxidative stress, and autophagy for reducing neuronal apoptosis. This review highlights the current evidence supporting the use of Xiaoyaosan as an antidepressant and provides an overview of the potential mechanisms involved.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Rui Liu, Chinese Academy of Medical Sciences, China
These authors have contributed equally to this work and share first authorship
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Claudia Bregonzio, CCT CONICET Córdoba, Argentina
Bechan Sharma, Allahabad University, India
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.925514